Opinion|Videos|February 13, 2025
Clinical Impact of Hypophosphatemia
Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Considering the incidence of hypophosphatemia in patients with IDA was significantly lower with the use of FDI and FXT than with FCM therapy, how does this impact the choice of treatment?
- How do you monitor phosphate levels?
- A retrospective analysis found a significantly higher combined event rate of fracture, radiological signs of osteomalacia, and kidney stones among patients treated with FCM than after ferric derisomaltose (FDI) treatment. Do these results impact your clinical decision-making?
- What potential interventions or preventative measures could be taken to mitigate the risk of hypophosphatemia in patients receiving IV iron formulations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
3
Clinical Trial Data Signal a New Era for Atopic Dermatitis, Melanoma, and Psoriasis
4
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
5
